Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer

This publication has 39 references indexed in Scilit:

• Patient-derived models of acquired resistance can identify effective drug combinations for cancer
  Science, 2014
• MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
  PLOS ONE, 2014
• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
  Journal of Clinical Oncology, 2013
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
  Science Translational Medicine, 2011
• High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
  Journal of Thoracic Oncology, 2010
• Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
  Cancer Cell, 2010
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
  Nature, 2009
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
  Proceedings of the National Academy of Sciences, 2008
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
  Science, 2007
• dbSNP: the NCBI database of genetic variation
  Nucleic Acids Research, 2001